BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

323 related articles for article (PubMed ID: 26398122)

  • 21. Stromal-derived factor-1 deficiency in the bone marrow of acute myeloid leukemia.
    Ge J; Hou R; Liu Q; Zhu R; Liu K
    Int J Hematol; 2011 Jun; 93(6):750-759. PubMed ID: 21607655
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The CXCR4 antagonist AMD3100 impairs survival of human AML cells and induces their differentiation.
    Tavor S; Eisenbach M; Jacob-Hirsch J; Golan T; Petit I; Benzion K; Kay S; Baron S; Amariglio N; Deutsch V; Naparstek E; Rechavi G
    Leukemia; 2008 Dec; 22(12):2151-5158. PubMed ID: 18769446
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Phenotypic alteration of bone marrow HSC and microenvironmental association in experimentally induced leukemia.
    Basak P; Chatterjee S; Das M; Das P; Pereira JA; Dutta RK; Chaklader M; Chaudhuri S; Law S
    Curr Stem Cell Res Ther; 2010 Dec; 5(4):379-86. PubMed ID: 20528754
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A phase 1 study of the CXCR4 antagonist plerixafor in combination with high-dose cytarabine and etoposide in children with relapsed or refractory acute leukemias or myelodysplastic syndrome: A Pediatric Oncology Experimental Therapeutics Investigators' Consortium study (POE 10-03).
    Cooper TM; Sison EAR; Baker SD; Li L; Ahmed A; Trippett T; Gore L; Macy ME; Narendran A; August K; Absalon MJ; Boklan J; Pollard J; Magoon D; Brown PA
    Pediatr Blood Cancer; 2017 Aug; 64(8):. PubMed ID: 28409853
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A phase 1/2 study of chemosensitization with the CXCR4 antagonist plerixafor in relapsed or refractory acute myeloid leukemia.
    Uy GL; Rettig MP; Motabi IH; McFarland K; Trinkaus KM; Hladnik LM; Kulkarni S; Abboud CN; Cashen AF; Stockerl-Goldstein KE; Vij R; Westervelt P; DiPersio JF
    Blood; 2012 Apr; 119(17):3917-24. PubMed ID: 22308295
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Functional potentials of human hematopoietic progenitor cells are maintained by mesenchymal stromal cells and not impaired by plerixafor.
    Ludwig A; Saffrich R; Eckstein V; Bruckner T; Wagner W; Ho AD; Wuchter P
    Cytotherapy; 2014 Jan; 16(1):111-21. PubMed ID: 24119647
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Identification of hepatic niche harboring human acute lymphoblastic leukemic cells via the SDF-1/CXCR4 axis.
    Kato I; Niwa A; Heike T; Fujino H; Saito MK; Umeda K; Hiramatsu H; Ito M; Morita M; Nishinaka Y; Adachi S; Ishikawa F; Nakahata T
    PLoS One; 2011; 6(11):e27042. PubMed ID: 22069486
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Inhibition of the SDF-1alpha-CXCR4 axis by the CXCR4 antagonist AMD3100 suppresses the migration of cultured cells from ATL patients and murine lymphoblastoid cells from HTLV-I Tax transgenic mice.
    Kawaguchi A; Orba Y; Kimura T; Iha H; Ogata M; Tsuji T; Ainai A; Sata T; Okamoto T; Hall WW; Sawa H; Hasegawa H
    Blood; 2009 Oct; 114(14):2961-8. PubMed ID: 19657116
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Therapeutically targeting SELF-reinforcing leukemic niches in acute myeloid leukemia: A worthy endeavor?
    Bernasconi P; Farina M; Boni M; Dambruoso I; Calvello C
    Am J Hematol; 2016 May; 91(5):507-17. PubMed ID: 26822317
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A designed peptide targeting CXCR4 displays anti-acute myelocytic leukemia activity in vitro and in vivo.
    Li X; Guo H; Yang Y; Meng J; Liu J; Wang C; Xu H
    Sci Rep; 2014 Oct; 4():6610. PubMed ID: 25312253
    [TBL] [Abstract][Full Text] [Related]  

  • 31. An Auristatin nanoconjugate targeting CXCR4+ leukemic cells blocks acute myeloid leukemia dissemination.
    Pallarès V; Unzueta U; Falgàs A; Sánchez-García L; Serna N; Gallardo A; Morris GA; Alba-Castellón L; Álamo P; Sierra J; Villaverde A; Vázquez E; Casanova I; Mangues R
    J Hematol Oncol; 2020 Apr; 13(1):36. PubMed ID: 32295630
    [TBL] [Abstract][Full Text] [Related]  

  • 32. CXCR4 regulates migration and development of human acute myelogenous leukemia stem cells in transplanted NOD/SCID mice.
    Tavor S; Petit I; Porozov S; Avigdor A; Dar A; Leider-Trejo L; Shemtov N; Deutsch V; Naparstek E; Nagler A; Lapidot T
    Cancer Res; 2004 Apr; 64(8):2817-24. PubMed ID: 15087398
    [TBL] [Abstract][Full Text] [Related]  

  • 33. MEIS1-mediated transactivation of synaptotagmin-like 1 promotes CXCL12/CXCR4 signaling and leukemogenesis.
    Yokoyama T; Nakatake M; Kuwata T; Couzinet A; Goitsuka R; Tsutsumi S; Aburatani H; Valk PJ; Delwel R; Nakamura T
    J Clin Invest; 2016 May; 126(5):1664-78. PubMed ID: 27018596
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Migratory behavior of leukemic cells from acute myeloid leukemia patients.
    Voermans C; van Heese WP; de Jong I; Gerritsen WR; van Der Schoot CE
    Leukemia; 2002 Apr; 16(4):650-7. PubMed ID: 11960346
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Targeting primary acute myeloid leukemia with a new CXCR4 antagonist IgG1 antibody (PF-06747143).
    Zhang Y; Saavedra E; Tang R; Gu Y; Lappin P; Trajkovic D; Liu SH; Smeal T; Fantin V; De Botton S; Legrand O; Delhommeau F; Pernasetti F; Louache F
    Sci Rep; 2017 Aug; 7(1):7305. PubMed ID: 28779088
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The role of polymorphisms of stromal-derived factor-1 and CXC receptor 4 in acute myeloid leukemia and leukemia cell dissemination.
    Zheng Q; Shuai X; Ye Y; Jin Y; Jiang N; Chen X; Su J
    Gene; 2016 Aug; 588(2):103-8. PubMed ID: 27154815
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Inhibition of CXCR4 with the novel RCP168 peptide overcomes stroma-mediated chemoresistance in chronic and acute leukemias.
    Zeng Z; Samudio IJ; Munsell M; An J; Huang Z; Estey E; Andreeff M; Konopleva M
    Mol Cancer Ther; 2006 Dec; 5(12):3113-21. PubMed ID: 17172414
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Evidence for the involvement of sphingosine-1-phosphate in the homing and engraftment of hematopoietic stem cells to bone marrow.
    Adamiak M; Borkowska S; Wysoczynski M; Suszynska M; Kucia M; Rokosh G; Abdel-Latif A; Ratajczak J; Ratajczak MZ
    Oncotarget; 2015 Aug; 6(22):18819-28. PubMed ID: 26299919
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cathepsin K cleavage of SDF-1α inhibits its chemotactic activity towards glioblastoma stem-like cells.
    Hira VV; Verbovšek U; Breznik B; Srdič M; Novinec M; Kakar H; Wormer J; der Swaan BV; Lenarčič B; Juliano L; Mehta S; Van Noorden CJ; Lah TT
    Biochim Biophys Acta Mol Cell Res; 2017 Mar; 1864(3):594-603. PubMed ID: 28040478
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A critical role of Src family kinase in SDF-1/CXCR4-mediated bone-marrow progenitor cell recruitment to the ischemic heart.
    Cheng M; Huang K; Zhou J; Yan D; Tang YL; Zhao TC; Miller RJ; Kishore R; Losordo DW; Qin G
    J Mol Cell Cardiol; 2015 Apr; 81():49-53. PubMed ID: 25655934
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.